Published in Eur Neuropsychopharmacol on July 01, 2009
Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression | NCT00157547
Baseline and treatment-emergent EEG biomarkers of antidepressant medication response do not predict response to repetitive transcranial magnetic stimulation. Brain Stimul (2013) 2.03
Remission prognosis for cognitive therapy for recurrent depression using the pupil: utility and neural correlates. Biol Psychiatry (2011) 1.23
Biomarkers to predict antidepressant response. Curr Psychiatry Rep (2010) 1.14
Computational psychiatry as a bridge from neuroscience to clinical applications. Nat Neurosci (2016) 1.04
Pretreatment anterior cingulate activity predicts antidepressant treatment response in major depressive episodes. Eur Arch Psychiatry Clin Neurosci (2013) 0.90
A preliminary study of the neural mechanisms of frustration in pediatric bipolar disorder using magnetoencephalography. Depress Anxiety (2010) 0.89
General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci (2011) 0.82
Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder. Dialogues Clin Neurosci (2014) 0.80
Biomarker Development for Brain-Based Disorders: Recent Progress in Psychiatry. J Neurol Psychol (2013) 0.79
Current source density analysis of resting state EEG in depression: a review. J Neural Transm (Vienna) (2015) 0.79
The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine. J Clin Neurophysiol (2011) 0.78
Role of Reward Sensitivity and Processing in Major Depressive and Bipolar Spectrum Disorders. Behav Ther (2016) 0.76
The effectiveness of prefrontal theta cordance and early reduction of depressive symptoms in the prediction of antidepressant treatment outcome in patients with resistant depression: analysis of naturalistic data. Eur Arch Psychiatry Clin Neurosci (2014) 0.76
Brain arousal regulation as response predictor for antidepressant therapy in major depression. Sci Rep (2017) 0.75
A wavelet-based technique to predict treatment outcome for Major Depressive Disorder. PLoS One (2017) 0.75
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials (2004) 6.64
A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry (2012) 6.34
Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA (2006) 6.26
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med (2006) 6.00
Medication augmentation after the failure of SSRIs for depression. N Engl J Med (2006) 5.16
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry (2008) 4.98
Hospital stay and mortality are increased in patients having a "triple low" of low blood pressure, low bispectral index, and low minimum alveolar concentration of volatile anesthesia. Anesthesiology (2012) 4.22
Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry (2009) 3.96
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry (2006) 3.90
Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology (2006) 3.80
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry (2012) 3.73
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol (2008) 3.65
Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2003) 3.60
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry (2011) 3.34
An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry (2005) 3.03
Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task. J Psychiatr Res (2008) 3.01
Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry (2006) 3.01
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry (2006) 2.90
Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry (2006) 2.85
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry (2007) 2.84
The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2006) 2.68
Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. Am J Psychiatry (2011) 2.58
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet (2006) 2.55
S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry (2010) 2.52
Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol Psychiatry (2010) 2.45
Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. Am J Psychiatry (2008) 2.42
Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med (2009) 2.34
Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA (2003) 2.30
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol (2008) 2.23
A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry (2006) 2.21
Depression and public health: an overview. J Psychosom Res (2002) 2.18
Bereavement and the diagnosis of major depressive episode in the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry (2011) 2.15
Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry (2007) 2.10
A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry (2014) 2.10
The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep (2007) 2.08
Relaxation response induces temporal transcriptome changes in energy metabolism, insulin secretion and inflammatory pathways. PLoS One (2013) 2.05
Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry (2008) 1.92
A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry (2006) 1.90
Genome-wide association study of suicide attempts in mood disorder patients. Am J Psychiatry (2010) 1.85
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom (2012) 1.82
Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. Am J Psychiatry (2010) 1.82
Effect of age at onset on the course of major depressive disorder. Am J Psychiatry (2007) 1.78
What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv (2009) 1.77
Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol (2003) 1.77
Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J Clin Psychiatry (2005) 1.70
Integrating psychiatry and primary care improves acceptability to mental health services among Chinese Americans. Gen Hosp Psychiatry (2004) 1.69
Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry (2007) 1.68
Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry (2007) 1.67
Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med (2004) 1.64
The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. J Psychiatr Res (2010) 1.61
Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry (2012) 1.57
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J Clin Psychiatry (2008) 1.57
Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res (2011) 1.57
A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol (2006) 1.57
Children of currently depressed mothers: a STAR*D ancillary study. J Clin Psychiatry (2006) 1.57
Assuring that double-blind is blind. Am J Psychiatry (2010) 1.56
Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr (2009) 1.55
Factors affecting perceptual thresholds in epiretinal prostheses. Invest Ophthalmol Vis Sci (2008) 1.55
A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry (2013) 1.53
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry (2007) 1.53
Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry (2007) 1.53
Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr (2006) 1.53
Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry (2004) 1.52
Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord (2005) 1.49
The impact of nonclinical factors on care use for patients with depression: a STAR*D report. CNS Neurosci Ther (2009) 1.49
Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry (2003) 1.48
Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data. J Clin Psychiatry (2007) 1.45
Ventromedial prefrontal cortex and amygdala dysfunction during an anger induction positron emission tomography study in patients with major depressive disorder with anger attacks. Arch Gen Psychiatry (2004) 1.44
STAR*D: revising conventional wisdom. CNS Drugs (2009) 1.41
QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ (2013) 1.40
Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Res (2009) 1.40
Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. J Clin Psychiatry (2010) 1.38
Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry (2010) 1.38
Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry (2009) 1.38
Measurements of the effect of surface slant on perceived lightness. J Vis (2004) 1.35
Validation of the Patient Health Questionnaire-9 for depression screening among Chinese Americans. Compr Psychiatry (2007) 1.33
Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry (2006) 1.29
Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology (2008) 1.29
Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry (2010) 1.29
Microstructural abnormalities in subcortical reward circuitry of subjects with major depressive disorder. PLoS One (2010) 1.29
Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med (2008) 1.28
Cortical thickness abnormalities in cocaine addiction--a reflection of both drug use and a pre-existing disposition to drug abuse? Neuron (2008) 1.27